Status:
COMPLETED
Epidural Anesthesia and Long-term Outcomes in Elderly Patients After Surgery
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
Peking University People's Hospital
Peking University Third Hospital
Conditions:
Elderly Patients
Solid Organ Cancer
Eligibility:
All Genders
60-90 years
Phase:
NA
Brief Summary
Surgical resection is one of the most important treatments for solid organ cancer. Whereas cancer recurrence and/or metastasis are the major reasons of treatment failure. The outcomes after surgery ar...
Detailed Description
Surgical resection is the main treatment for potentially curable solid organ cancer. However, long-term survival after cancer surgery is far from satisfactory. Quite a number of patients develop tumor...
Eligibility Criteria
Inclusion
- Elderly patients (age 60-90 years);
- Scheduled to undergo noncardiac thoracic or abdominal surgery with an expected duration of 2 hours or longer. For those who undergo thoracoscopic or laparoscopic surgery, the expected length of incision must be 5 centimeters or more;
- Agree to receive patient-controlled postoperative analgesia.
Exclusion
- Refused to participate;
- Previous history of schizophrenia, epilepsy or Parkinson disease, or unable to complete preoperative assessment due to severe dementia, language barrier or end-stage disease;
- History of myocardial infarction or stroke within 3 months before surgery;
- Presence of any contraindication to epidural anesthesia and analgesia, including abnormal vertebral anatomy, previous spinal trauma or surgery, severe chronic back pain, coagulation disorder (prothrombin time or activated partial prothrombin time longer than 1.5 times of the upper normal limit, or platelet count of less than 80 \* 10\^9/L), local infection near the site of puncture, and severe sepsis;
- Severe heart dysfunction (New York Heart Association functional classification 3 or above), severe hepatic insufficiency (Child-Pugh grade C), or severe renal insufficiency (serum creatinine of 442 umol/L or above, with or without serum potassium of 6.5 mmol/L or above, or requirement of renal replacement therapy);
- Any other conditions that were considered unsuitable for study participation.
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
1802 Patients enrolled
Trial Details
Trial ID
NCT03335826
Start Date
August 1 2017
End Date
September 30 2019
Last Update
April 14 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing University First Hospital
Beijing, Beijing Municipality, China, 100034
2
Beijing Shijitan Hospital
Beijing, China, 100038
3
Peking University People's Hospital
Beijing, China, 100044
4
Peking University Third Hospital
Beijing, China, 100191